Market research

IMA ImageneBio, Inc.

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 57M
P/E ratio: Not available
Analyst target: 18
Dividend yield: Not available
Beta: Not available

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US45175G2075
Market cap: 57M
P/E ratio: Not available
Analyst target: 18
Dividend yield: Not available
Beta: Not available

About

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about IMA.

IMA ImageneBio, Inc.

Price & volume

Company facts

About ImageneBio, Inc.

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet